Breast Cancer (HTAN, 2022)

Summary

Breast Cancer (HTAN, 2022) is a study catalogued by cBioPortal DataHub under the cancer-type code brca. EvidenceHelix groups it with breast studies.

Study description

An omic and multidimensional spatial (OMS) atlas generated from four serial biopsies of an individual with metastatic breast cancer during 3.5 years of therapy. This resource links detailed, longitudinal clinical metadata including treatment times and doses, anatomic imaging, and blood-based response measurements to comprehensive DNA, RNA, and protein profiles. These data report aspects of heterogeneity and evolution of the cancer genome, signaling pathways, immune microenvironment, cellular composition and organization, and ultrastructure (Johnson et al., Cell Reports Medicine, 2022).

Text as published in the source's study metadata.

Citation & PubMed

Johnson BE, Creason AL, Stommel JM et al. An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. Cell Rep Med. 2022 Feb 15;3(2):100525.

Linked PubMed records: PMID 35243422

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

brca_hta9_htan_2022

Short name

brca_hta9_htan_2022

Source cancer-type code

brca

Reference genome

not given

Source access groups

PUBLIC

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Johnson BE, Creason AL, Stommel JM et al. An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. Cell Rep Med. 2022 Feb 15;3(2):100525.

• PubMed record 35243422 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)

  Targeted sequencing of 2509 primary breast tumors with 548 matched normals.

  BreastOther published and consortium studiesSource code brcaPubMed 3

• Breast Cancer (SMC 2018)

  Whole-exome sequencing of 187 primary tumors from a Korean breast cancer cohort (SMC).

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Breast Cancer Xenografts (British Columbia, Nature 2015)

  Whole genome/targeted sequencing to evaluate the clonal dynamics in 116 breast cancer patient xenografts.

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Breast Invasive Carcinoma (British Columbia, Nature 2012)

  Whole genome/exome sequencing analysis of 65 breast cancer samples

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Breast Invasive Carcinoma (Broad, Nature 2012)

  Whole-exome sequencing of 103 breast cancer tumor/normal sample pairs. Generated by the Broad Institute.

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Breast Invasive Carcinoma (Sanger, Nature 2012)

  Whole exome sequencing from 100 breast cancer tumor/normal sample pairs. Generated by the Sanger Institute.

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Metastatic Breast Cancer (AURORA US Network, Nat Cancer 2023)

  Whole exome and low-pass whole genome sequencing of 55 patients with metastatic breast cancer (53 primary cancers and 102 metastases) and their matched normals. Retrospective Tissue Collection; an initiative of the Br…

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Metastatic Breast Cancer (DFCI, Cancer Discov 2020)

  Whole exome sequencing of 59 CDK4/6i exposed metastatic breast cancer tumors and their matched normals.

  BreastOther published and consortium studiesSource code brcaPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.